Zynerba Pharmaceuticals (ZYNE) Upgraded by ValuEngine to “Buy”

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Tuesday, April 30th, ValuEngine reports.

A number of other research firms also recently issued reports on ZYNE. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They set a “buy” rating and a $36.00 price objective on the stock. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Saturday, January 19th. Cantor Fitzgerald reiterated a “buy” rating and set a $11.00 target price on shares of Zynerba Pharmaceuticals in a research note on Thursday, March 7th. HC Wainwright restated a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Monday,

... read more at: https://techknowbits.com/2019/05/15/zynerba-pharmaceuticals-zyne-upgraded-at-valuengine.html